MX2021010281A - Proteinas de enlace a antigenos que se enlazan al bcma. - Google Patents
Proteinas de enlace a antigenos que se enlazan al bcma.Info
- Publication number
- MX2021010281A MX2021010281A MX2021010281A MX2021010281A MX2021010281A MX 2021010281 A MX2021010281 A MX 2021010281A MX 2021010281 A MX2021010281 A MX 2021010281A MX 2021010281 A MX2021010281 A MX 2021010281A MX 2021010281 A MX2021010281 A MX 2021010281A
- Authority
- MX
- Mexico
- Prior art keywords
- bcma
- binding
- antibodies
- human
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810771P | 2019-02-26 | 2019-02-26 | |
| US201962811431P | 2019-02-27 | 2019-02-27 | |
| PCT/US2020/019763 WO2020176549A1 (en) | 2019-02-26 | 2020-02-25 | Antigen binding proteins that bind bcma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010281A true MX2021010281A (es) | 2021-09-23 |
Family
ID=72238662
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010281A MX2021010281A (es) | 2019-02-26 | 2020-02-25 | Proteinas de enlace a antigenos que se enlazan al bcma. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12630642B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3930852A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7554759B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210133261A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113874082B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020228367A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021016791A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3130765A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL285813A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021010281A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202109163YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020176549A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114650829A (zh) * | 2019-09-05 | 2022-06-21 | 索伦托药业有限公司 | 结合bcma的二聚体抗原受体(dar) |
| TWI917473B (zh) | 2020-11-02 | 2026-03-11 | 新加坡商蜂鳥生物科技私人有限公司 | Bcma/taci抗原結合分子 |
| KR20250152662A (ko) | 2020-12-31 | 2025-10-23 | 사노피 | NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자 |
| WO2022184082A1 (en) | 2021-03-03 | 2022-09-09 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates comprising an anti-bcma antibody |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| WO2023237366A1 (en) * | 2022-05-27 | 2023-12-14 | Sanofi | Anti-bcma antibodies |
| CN119841951B (zh) * | 2024-12-25 | 2025-10-14 | 厦门大学附属第一医院(厦门市第一医院、厦门市红十字会医院、厦门市糖尿病研究所) | 一种抗bcma抗体或其抗原结合片段及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| GB9908533D0 (en) * | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| US7214786B2 (en) * | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| CN1838968A (zh) * | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| JP5718640B2 (ja) * | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトc−fms抗原結合性タンパク質 |
| MX2015005546A (es) * | 2012-11-13 | 2015-08-05 | Regeneron Pharma | Anticuerpos anti-receptor de procineticinas (prokr) y usos de los mismos. |
| TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
| TW201632559A (zh) * | 2015-02-22 | 2016-09-16 | 索倫多醫療公司 | 結合cd137之抗體治療劑 |
| HUE057285T2 (hu) | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| TWI811023B (zh) * | 2015-08-17 | 2023-08-01 | 美商健生生物科技公司 | 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途 |
| MA44254A (fr) * | 2016-02-17 | 2018-12-26 | Seattle Genetics Inc | Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques |
| UA126813C2 (uk) * | 2017-08-01 | 2023-02-08 | Медімм'Юн, Ллк | Моноклональний кон’югат антитіло-лікарський засіб до bcma |
| US20200224160A1 (en) * | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| CN109265550B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Bcma抗体、嵌合抗原受体和药物 |
| CN114650829A (zh) * | 2019-09-05 | 2022-06-21 | 索伦托药业有限公司 | 结合bcma的二聚体抗原受体(dar) |
-
2020
- 2020-02-25 KR KR1020217030843A patent/KR20210133261A/ko not_active Withdrawn
- 2020-02-25 MX MX2021010281A patent/MX2021010281A/es unknown
- 2020-02-25 WO PCT/US2020/019763 patent/WO2020176549A1/en not_active Ceased
- 2020-02-25 EP EP20763127.6A patent/EP3930852A4/en not_active Withdrawn
- 2020-02-25 CA CA3130765A patent/CA3130765A1/en active Pending
- 2020-02-25 BR BR112021016791A patent/BR112021016791A2/pt not_active IP Right Cessation
- 2020-02-25 JP JP2021549630A patent/JP7554759B2/ja active Active
- 2020-02-25 SG SG11202109163YA patent/SG11202109163YA/en unknown
- 2020-02-25 AU AU2020228367A patent/AU2020228367A1/en not_active Abandoned
- 2020-02-25 CN CN202080031584.2A patent/CN113874082B/zh not_active Expired - Fee Related
-
2021
- 2021-08-23 IL IL285813A patent/IL285813A/en unknown
- 2021-08-25 US US17/412,089 patent/US12630642B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3930852A1 (en) | 2022-01-05 |
| WO2020176549A1 (en) | 2020-09-03 |
| CA3130765A1 (en) | 2020-09-03 |
| KR20210133261A (ko) | 2021-11-05 |
| US20210388097A1 (en) | 2021-12-16 |
| US12630642B2 (en) | 2026-05-19 |
| SG11202109163YA (en) | 2021-09-29 |
| EP3930852A4 (en) | 2022-12-28 |
| CN113874082B (zh) | 2024-12-06 |
| JP7554759B2 (ja) | 2024-09-20 |
| IL285813A (en) | 2021-10-31 |
| JP2022521956A (ja) | 2022-04-13 |
| BR112021016791A2 (pt) | 2021-11-16 |
| CN113874082A (zh) | 2021-12-31 |
| AU2020228367A1 (en) | 2021-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| CY1125429T1 (el) | Μουτεϊνες ιντερλευκινης-21 και μεθοδοι θεραπευτικης αγωγης | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| MX2021011696A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123. | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| PE20200006A1 (es) | Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap | |
| PE20181092A1 (es) | Anticuerpos anti-pd1 y metodos de uso | |
| EA201690377A1 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| CY1119647T1 (el) | Αντισωματα προσδεσης αλβουμινης και τμηματα προσδεσης αυτων | |
| CO2019001367A2 (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| CY1121132T1 (el) | ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1 | |
| EA201892774A1 (ru) | Антитела | |
| EA201991409A3 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| AR093357A1 (es) | Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer | |
| BR112021016791A2 (pt) | Proteínas de ligação de antígenos que se ligam a bcma | |
| AR074857A1 (es) | Proteinas de union al receptor cgrp (peptidos relacionados con el gen de calcitonina) humano | |
| CO6690759A2 (es) | Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb | |
| CL2021002168A1 (es) | Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407). | |
| EA202091166A1 (ru) | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc С ИЗМЕНЕННЫМ ГЛИКОЗИЛИРОВАНИЕМ И СНИЖЕННОЙ ЭФФЕКТОРНОЙ ФУНКЦИЕЙ | |
| AR110567A1 (es) | Conjugados específicos de anticuerpo-principio activo (adcs) con inhibidores de ksp (proteína del hueso de la quinecina) | |
| CO7170127A2 (es) | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 m(lag-3) y usos de los mismos | |
| ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
| AR095432A1 (es) | Proteínas de unión a antígeno |